Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.

Available treatments for lymphatic filariasis (LF) are limited in their longterm clearance of microfilaria from the blood. The safety and efficacy of a single-dose triple-drug therapy of the antifilarial drugs diethylcarbamazine (DEC), ivermectin (IVM), and albendazole (ALB) for LF are unknown. We performed a pilot study to test the efficacy, safety, and pharmacokinetics of single-dose DEC, IVM, and ALB in Wuchereria bancrofti-infected Papua New Guineans. Adults were randomized into 2 treatment arms, DEC 6 mg/kg + ALB 400 mg (N = 12) or DEC 6 mg/kg + ALB 400 mg + IVM 200 μg/kg (N = 12), and monitored for microfilaria, parasite antigenemia, adverse events (AEs), and serum drug levels. Triple-drug therapy induced >2-log reductions in microfilaria levels at 36 and 168 hours after treatment compared with approximately 1-log reduction with 2 drugs. All 12 individuals who received 3 drugs were microfilaria negative 1 year after treatment, whereas 11 of 12 individuals in the 2-drug regimen were microfilaria positive. In 6 participants followed 2 years after treatment, those who received 3 drugs remained microfilaria negative. AEs, particularly fever, myalgias, pruritus, and proteinuria/hematuria, occurred in 83% vs 50% of those receiving triple-drug compared to 2-drug treatment respectively (P = .021); all resolved within 7 days after treatment. No serious AEs were observed in either group. There was no significant effect of IVM on DEC or ALB drug levels. Triple-drug therapy is safe and more effective than DEC + ALB for Bancroftian filariasis and has the potential to accelerate elimination of lymphatic filariasis. NCT01975441.

Thomsen EK ，Sanuku N ，Baea M ，Satofan S ，Maki E ，Lombore B ，Schmidt MS ，Siba PM ，Weil GJ ，Kazura JW ，Fleckenstein LL ，King CL ... -  《-》

Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire.

Edi C ，Bjerum CM ，Ouattara AF ，Chhonker YS ，Penali LK ，Méité A ，Koudou BG ，Weil GJ ，King CL ，Murry DJ ... -  《PLoS Neglected Tropical Diseases》

Safety and efficacy of mass drug administration with a single-dose triple-drug regimen of albendazole + diethylcarbamazine + ivermectin for lymphatic filariasis in Papua New Guinea: An open-label, cluster-randomised trial.

Tavul L ，Laman M ，Howard C ，Kotty B ，Samuel A ，Bjerum C ，O'Brian K ，Kumai S ，Amuga M ，Lorry L ，Kerry Z ，Kualawi M ，Karl S ，Makita L ，John LN ，Bieb S ，Wangi J ，Weil GJ ，Goss CW ，Tisch DJ ，Pomat W ，King CL ，Robinson LJ ... -  《PLoS Neglected Tropical Diseases》

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.

Jambulingam P ，Kuttiatt VS ，Krishnamoorthy K ，Subramanian S ，Srividya A ，Raju HKK ，Rahi M ，Somani RK ，Suryaprakash MK ，Dwivedi GP ，Weil GJ ... -  《PLoS Neglected Tropical Diseases》

A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.

King CL ，Suamani J ，Sanuku N ，Cheng YC ，Satofan S ，Mancuso B ，Goss CW ，Robinson LJ ，Siba PM ，Weil GJ ，Kazura JW ... -  《-》